2I3 Stock Chart & Stats
€4.18
-€0.10(-1.90%)
At close: 4:00 PM EDT
€4.18
-€0.10(-1.90%)
Day’s Range― - ―
52-Week Range€4.02 - €6.75
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€60.10M
Enterprise Value€81.67M
Total Cash (Recent Filing)€4.36M
Total Debt (Recent Filing)€10.97M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Dec 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding13,918,569
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)20.93
Price to Sales (P/S)1.39
P/FCF Ratio-16.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.09
Revenue Forecast (FY)€58.11M
Bulls Say, Bears Say
Bulls Say
Margin And EBITDA ImprovementThe combination of revenue growth, sharply higher gross margin, and sustained adjusted EBITDA profitability indicates improving operating leverage in the core services business. If maintained, this progress can strengthen internal funding capacity and support more durable earnings improvement over the next several quarters.
Tumor Bank And Data DifferentiationA high-quality tumor bank and clinically annotated patient-derived data can differentiate Champions in oncology research services, where customers need credible translational evidence. This specialized asset base may support customer retention, pricing power, and expansion of service and data opportunities over time.
Growing Data Licensing PlatformThe emergence of meaningful data licensing revenue broadens Champions’ business beyond fee-for-service studies and creates a potentially scalable monetization channel. A robust pipeline and growing customer base could improve revenue mix and increase the strategic value of the company’s proprietary oncology data.
Bears Say
Revenue And Profitability VolatilityThe recent contraction in revenue and return to a net loss show that improved quarterly execution has not yet translated into consistent company-wide profitability. The history of swings between losses and profit reduces earnings visibility and makes sustained operating progress harder to establish.
Cash Burn And Elevated LeverageNegative operating and free cash flow mean the business is currently consuming rather than generating cash, while higher leverage reduces financial flexibility. Persistent cash burn could constrain investment in growth initiatives and increase reliance on financing if operating performance weakens.
Lumpy Revenue And Corellia UncertaintyLumpy licensing contracts can make revenue and cash generation uneven, complicating planning and weakening near-term earnings visibility. Corellia’s uncertain funding or licensing outcome also leaves current investment commitments unresolved and makes any expected resource redeployment conditional.
Champions Oncology News
2I3 FAQ
What was Champions Oncology Inc’s price range in the past 12 months?
Champions Oncology Inc lowest stock price was €4.02 and its highest was €6.75 in the past 12 months.
What is Champions Oncology Inc’s market cap?
Champions Oncology Inc’s market cap is €60.10M.
When is Champions Oncology Inc’s upcoming earnings report date?
Champions Oncology Inc’s upcoming earnings report date is Dec 15, 2026 which is in 53 days.
How were Champions Oncology Inc’s earnings last quarter?
Champions Oncology Inc released its earnings results on Sep 10, 2026. The company reported €0.043 earnings per share for the quarter.
Is Champions Oncology Inc overvalued?
According to Wall Street analysts Champions Oncology Inc’s price is currently Overvalued.
Does Champions Oncology Inc pay dividends?
Champions Oncology Inc does not currently pay dividends.
What is Champions Oncology Inc’s EPS estimate?
Champions Oncology Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Champions Oncology Inc have?
Champions Oncology Inc has 13,918,569 shares outstanding.
What happened to Champions Oncology Inc’s price movement after its last earnings report?
Champions Oncology Inc reported an EPS of €0.043 in its last earnings report. Following the earnings report the stock price went up 2.871%.
Which hedge fund is a major shareholder of Champions Oncology Inc?
Currently, no hedge funds are holding shares in DE:2I3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Champions Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.95%
12-Months-Change
Fundamentals
Return on Equity
-27.88%
Trailing 12-Months
Asset Growth
8.98%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Champions Oncology Inc
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
2I3 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive overall. Management reported approximately 9% revenue growth, significant gross and oncology services margin expansion, the fifth consecutive quarter of positive adjusted EBITDA, stronger data licensing revenue, healthy services demand, and continued Corellia progress. The main cautions were the remaining GAAP net loss, cash usage, lumpy timing of data licensing revenue, higher sales and marketing expense from planned investment, and uncertainty around the timing of a Corellia funding or licensing outcome.View all DE:2I3 earnings summariesTechnical Analysis
Oncolytics Biotech
―
―
Cardiff Oncology
―
MaxCyte
―
Black Diamond Therapeutics
―
Lantern Pharma
―